TIxchiq is approved for individuals aged 18 and older, especially those at an increased risk of exposure to the chikungunya virus
TIxchiq is approved for individuals aged 18 and older, especially those at an increased risk of exposure to the chikungunya virus
Chikungunya
Chikungunya is a global health concern transmitted through mosquito bites, with over 5 million reported cases in the past 15 years.
Symptoms
Common symptoms include fever and joint pain, while others may experience a rash, headache, and muscle pain. Severe joint pain lasting for months is possible for some individuals.
Treatment
Treatment involves rest, fluids, and over-the-counter medications for pain and fever management.
Treatment involves rest, fluids, and over-the-counter medications for pain and fever management.
Ixchiq
Ixchiq addresses an unmet medical need, offering a vital preventive measure for a potentially debilitating disease with limited treatment options.
Safety
Ixchiq contains a live, weakened chikungunya virus. Side effects may include headache, fatigue, muscle and joint pain and fevers.